REFERENCES
1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
2. Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, et al. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat 2019;46:100645.
3. Yang J, Antin P, Berx G, Blanpain C, Brabletz T, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2020;21:341-52.
4. Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic Plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell 2019;24:65-78.
5. Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell 2020;37:471-84.
6. Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol 2019;29:212-26.
7. Saygin C, Matei D, Majeti R, Reizes O, Lathia JD. Targeting cancer stemness in the clinic: from hype to hope. Cell Stem Cell 2019;24:25-40.
10. Juin P, Geneste O, Gautier F, Depil S, Campone M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer 2013;13:455-65.
11. Brocard E, Oizel K, Lalier L, Pecqueur C, Paris F, et al. Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling. Oncotarget 2015;6:6840-9.
12. Valès S, Bacola G, Biraud M, Touvron M, Bessard A, et al. Tumor cells hijack enteric glia to activate colon cancer stem cells and stimulate tumorigenesis. EBioMedicine 2019;49:172-88.
13. Balaban NQ, Helaine S, Lewis K, Ackermann M, Aldridge B, et al. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol 2019;17:441-8.
14. Guler GD, Tindell CA, Pitti R, Wilson C, Nichols K, et al. Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure. Cancer Cell 2017;32:221-37.e13.
15. Ravindran Menon D, Hammerlindl H, Torrano J, Schaider H, Fujita M. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Theranostics 2020;10:6261-77.
16. Vallette FM, Olivier C, Lézot F, Oliver L, Cochonneau D, et al. Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer. Biochem Pharmacol 2019;162:169-76.
17. Hammerlindl H, Schaider H. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance. J Cell Commun Signal 2018;12:133-41.
18. Ramirez M, Rajaram S, Steininger RJ, Osipchuk D, Roth MA, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun 2016;7:10690.
22. Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 2001;1:13-9.
23. Talhaoui I, Matkarimov BT, Tchenio T, Zharkov DO, Saparbaev MK. Aberrant base excision repair pathway of oxidatively damaged DNA: implications for degenerative diseases. Free Radic Biol Med 2017;107:266-77.
24. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, et al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 2010;97:311-22.
25. Cartron PF, Hervouet E, Debien E, Olivier C, Pouliquen D, et al. Folate supplementation limits the tumourigenesis in rodent models of gliomagenesis. Eur J Cancer 2012;48:2431-41.
26. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
27. Hervouet E, Debien E, Campion L, Charbord J, Menanteau J, et al. Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation. Clin Cancer Res 2009;15:3519-29.
28. Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, et al. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer 2010;127:2106-18.
29. Wiewrodt D, Nagel G, Dreimüller N, Hundsberger T, Perneczky A, et al. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int J Cancer 2008;122:1391-9.
30. Zhang Y, Dube C, Gibert M Jr, Cruickshanks N, Wang B, et al. The p53 pathway in glioblastoma. Cancers (Basel) 2018;10:297.
31. Belter A, Barciszewski J, Barciszewska AM. Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions. PLoS One 2020;15:e0229534.
32. Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, et al. p53 small molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res 2008;68:10034-9.
33. He F, Borcherds W, Song T, Wei X, Das M, et al. Interaction between p53 N terminus and core domain regulates specific and nonspecific DNA binding. Proc Natl Acad Sci U S A 2019;116:8859-68.
34. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
35. O’Regan CJ, Kearney H, Beausang A, Farrell MA, Brett FM, et al. Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol. J Neurooncol 2018;137:233-40.
36. Chen X, Zhang M, Gan H, Wang H, Lee JH, et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 2018;9:2949.
37. de Souza CF, Sabedot TS, Malta TM, Stetson L, Morozova O, et al. A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence. Cell Rep 2018;23:637-51.
38. Lu C, Wei Y, Wang X, Zhang Z, Yin J, et al. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer 2020;19:28.
39. Briand J, Nadaradjane A, Bougras-Cartron G, Olivier C, Vallette FM, et al. Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation. Clin Epigenetics 2019;11:159.
40. Banelli B, Daga A, Forlani A, Allemanni G, Marubbi D, et al. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. Oncotarget 2017;8:34896-910.
41. Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell 2017;20:233-46.e7.
42. Wang Z, Jiang W, Wang Y, Guo Y, Cong Z, et al. MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma. Biomed Rep 2015;3:543-8.
43. Nadaradjane A, Briand J, Bougras-Cartron G, Disdero V, Vallette FM, et al. MiR-370-3p is a therapeutic tool in anti-glioblastoma therapy but is not an intratumoral or cell-free circulating biomarker. Mol Ther Nucleic Acids 2018;13:642-50.
44. Estaquier J, Vallette F, Vayssiere JL, Mignotte B. The mitochondrial pathways of apoptosis. Adv Exp Med Biol 2012;942:157-83.
45. Rossin A, Miloro G, Hueber AO. TRAIL and FasL functions in cancer and autoimmune diseases: towards an increasing complexity. Cancers (Basel) 2019;11:639.
46. Trejo-Solís C, Serrano-Garcia N, Escamilla-Ramírez Á, Castillo-Rodríguez RA, Jimenez-Farfan D, et al. Autophagic and apoptotic pathways as targets for chemotherapy in glioblastoma. Int J Mol Sci 2018;19:3773.
47. Cartron PF, Loussouarn D, Campone M, Martin SA, Vallette FM. Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme. Cell Death Dis 2012;3:e421.
48. Martin S, Toquet C, Oliver L, Cartron PF, Perrin P, et al. Expression of bcl-2, bax and bcl-xl in human gliomas: a re-appraisal. J Neurooncol 2001;52:129-39.
49. Manero F, Gautier F, Gallenne T, Cauquil N, Grée D, et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 2006;66:2757-64.
50. Gratas C, Séry Q, Rabé M, Oliver L, Vallette FM. Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma. Oncotarget 2014;5:2428-35.
51. Chang J, Wang Y, Shao L, Laberge RM, Demaria M, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 2016;22:78-83.
52. Yamaguchi R, Perkins G. Finding a Panacea among combination cancer therapies. Cancer Res 2012;72:18-23.
53. Taylor MA, Das BC, Ray SK. Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma. Apoptosis 2018;23:563-75.
54. Buccarelli M, Marconi M, Pacioni S, De Pascalis I, D’Alessandris QG, et al. Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. Cell Death Dis 2018;9:841.
55. Pawlowska E, Szczepanska J, Szatkowska M, Blasiak J. An interplay between senescence, apoptosis and autophagy in glioblastoma multiforme - role in pathogenesis and therapeutic perspective. Int J Mol Sci 2018;19:889.
56. Ulasov IV, Lenz G, Lesniak MS. Autophagy in glioma cells: an identity crisis with a clinical perspective. Cancer Lett 2018;428:139-46.
57. Aasland D, Götzinger L, Hauck L, Berte N, Meyer J, et al. Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF-κB. Cancer Res 2019;79:99-113.
58. Jeon HY, Kim JK, Ham SW, Oh SY, Kim J, et al. Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype. Tumour Biol 2016;37:5857-67.
59. Tomicic MT, Christmann M. Targeting anticancer drug-induced senescence in glioblastoma therapy. Oncotarget 2018;9:37466-7.
60. Gammoh N, Fraser J, Puente C, Syred HM, Kang H, et al. Suppression of autophagy impedes glioblastoma development and induces senescence. Autophagy 2016;12:1431-9.
61. Tien AC, Li J, Bao X, Derogatis A, Kim S, et al. A phase 0 trial of Ribociclib in recurrent glioblastoma patients incorporating a tumor pharmacodynamic- andpharmacokinetic-guided expansion cohort. Clin Cancer Res 2019;25:5777-86.
62. Nagy A, Eder K, Selak MA, Kalman B. Mitochondrial energy metabolism and apoptosis regulation in glioblastoma. Brain Res 2015;1595:127-42.
63. Oizel K, Chauvin C, Oliver L, Gratas C, Geraldo F, et al. Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity. Clin Cancer Res 2017;23:6292-304.
64. Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 2018;560:243-7.
65. Zhu Z, Du S, Du Y, Ren J, Ying G, et al. Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. J Neurochem 2018;144:93-104.
66. Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, et al. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis 2015;6:e1601.
67. Lo Dico A, Salvatore A, Martelli C, Ronchi D, Diceglie C, et al. Intracellular redox-balance involvement in temozolomide resistance-related molecular mechanisms in glioblastoma. Cells 2019;8:1315.
68. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010;2:31ra34.
69. Morfouace M, Lalier L, Bahut M, Bonnamain V, Naveilhan P, et al. Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications. J Biol Chem 2012;287:33664-74.
70. Morfouace M, Lalier L, Oliver L, Cheray M, Pecqueur C, et al. Control of glioma cell death and differentiation by PKM2-Oct4 interaction. Cell Death Dis 2014;5:e1036.
71. Shen L, Zhu J, Chen F, Lin W, Cai J, et al. RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: an in vivo study. BMC Cancer 2015;15:970.
72. Oizel K, Gratas C, Nadaradjane A, Oliver L, Vallette FM, et al. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH. Cell Death Dis 2015;6:e1704.
73. Lin H, Patel S, Affleck VS, Wilson I, Turnbull DM, et al. Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells. Neuro Oncol 2017;19:43-54.
74. Al-Nedawi K, Meehan J, Micallef V, Lhotak L, May A, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008;10:619-24.
75. Corcoran C, Rani S, O’Brien K, O’Neill A, Prencipe M, et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One 2012;7:e50999.
76. Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst 2015;107:djv135.
77. Mao L, Li J, Chen WX, Cai YQ, Yu DD, et al. Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs. Tumour Biol 2016;37:5247-56.
78. Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of Glioblastoma immunotherapy. J Neurooncol 2020; doi: 10.1007/s11060-020-03448-1.
79. Chauvin C, Joalland N, Perroteau J, Jarry U, Lafrance L, et al. NKG2D controls natural reactivity of Vγ9Vδ2 T lymphocytes against mesenchymal glioblastoma cells. Clin Cancer Res 2019;25:7218-28.
80. Sengupta S, Marrinan J, Frishman C, Sampath P. Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol 2012;2012:831090.
81. Candolfi M, Yagiz K, Wibowo M, Ahlzadeh GE, Puntel M, et al. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res 2014;20:1555-65.
82. Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol 2018;20:1566-72.
83. Noh H, Zhao Q, Yan J, Kong LY, Gabrusiewicz K, et al. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett 2018;433:176-85.
84. Fleurence J, Bahri M, Fougeray S, Faraj S, Vermeulen S, et al. Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside. Int J Cancer 2020;146:424-38.
85. Karachi A, Yang C, Dastmalchi F, Sayour EJ, Huang J, et al. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol 2019;21:730-41.
86. Wei J, Chen P, Gupta P, Ott M, Zamler D, et al. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol 2020;22:180-94.
87. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
88. Gimple RC, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev 2019;33:591-609.
89. Aderetti DA, Hira VVV, Molenaar RJ, van Noorden CJF. The hypoxic peri-arteriolar glioma stem cell niche, an integrated concept of five types of niches in human glioblastoma. Biochim Biophys Acta Rev Cancer 2018;1869:346-54.
90. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
91. Rabé M, Dumont S, Álvarez-Arenas A, Janati H, Belmonte-Beitia J, et al. Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. Cell Death Dis 2020;11:19.
92. Hoang-Minh LB, Siebzehnrubl FA, Yang C, Suzuki-Hatano S, Dajac K, et al. Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma. EMBO J 2018;37:e98772.
93. Quinones A, Le A. The multifaceted metabolism of glioblastoma. Adv Exp Med Biol 2018;1063:59-72.
94. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 2019;20:69-84.
95. Fedele M, Cerchia L, Pegoraro S, Sgarra R, Manfioletti G. Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma. Int J Mol Sci 2019;20:2746.
